H19: A Regulatory Biomarker with Prognostic Value in Leukemias
There are pieces of evidence indicating the important role of long noncoding RNAs (lncRNA) with transcription factors and their effect on gene expression at transcription and epigenetic levels. The possible role of lncRNAs in humans have been investigated the involvement of H19 in cancers, including leukemia. H19 inhibits the transcription of IGF2 receptor via miR-675 and thereby regulates IGF-2 signaling. In chronic myeloproliferative disorders (CMPD), bone marrow cells of patients express H19 in significantly lower levels than healthy samples, and the reduced expression of H19 through IGF-2 reinforces the growth signal. H19 plays a regulatory role in maintaining the proliferation and selfrenewal abilities of HSCs. This molecule also influences the pathogenesis of leukemia due to its role in increasing the proliferation and regulating the quiescence of stem cells. Accordingly, it may be possible to consider H19 as a prognostic biomarker for myeloid disorders. In this review, the probable regulatory role of H19 as a prognostic biomarker with a variable role dependent upon disease context will be discussed.
Chen S, Liang H, Yang H, Zhou K, Xu L, Liu J, et al. Long noncoding RNAs: The novel diagnostic biomarkers for leukemia. Environmental toxicology and pharmacology 2017;55:81–6.
2. Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. Cancer genetics 2017;216:105–10.
3. He H, Wang N, Yi X, Tang C, Wang D. Long non-coding RNA H19 regulates E2F1 expression by competitively sponging endogenous miR-29a-3p in clear cell renal cell carcinoma. Cell & Bioscience 2017;7:65.
4. Li H, Li J, Jia S, Wu M, An J, Zheng Q, et al. miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer. Oncotarget 2015;6:31958.
5. Zhang E-B, Han L, Yin D-D, Kong R, De W, Chen J. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Medical oncology 2014;31:914.
6. Alvarez-Dominguez JR, Hu W, Gromatzky AA, Lodish HF. Long noncoding RNAs during normal and malignant hematopoiesis. International journal of hematology 2014;99:531–41.
7. Jarroux J, Morillon A, Pinskaya M. History, Discovery, and classification of lncRNAs. Long Non Coding RNA Biology: Springer; 2017;1–46.
8. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 2014;5:2318.
9. Shahjahani M, Khodadi E, Seghatoleslami M, Asl JM, Golchin N, Zaieri ZD, Saki N. Rare cytogenetic abnormalities and alteration of microRNAs in acute myeloid leukemia and response to therapy. Oncology reviews 2015;10;9.
10. Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 2014;1839:1097–109.
11. Tessema M, Länger F, Bock O, Seltsam A, Metzig K, Hasemeier B, et al. Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. International journal of oncology 2005;26:499–507.
12. Zhou Jd, Lin J, Zhang Tj, Ma Jc, Li Xx, Wen Xm, et al. Hypomethylation‐mediated H19 overexpression increases the risk of disease evolution through the association with BCR‐ ABL transcript in chronic myeloid leukemia. Journal of cellular physiology. 2017.
13. Bock O, Schlue J, Kreipe H. Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders. Leukemia 2003;17:815.
14. Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan L, et al. High expression of long non‐coding RNA H19 is required for efficient tumorigenesis induced by Bcr‐Abl oncogene. FEBS letters. 2014;588:1780–6.
15. Saki N, Abroun S, Soleimani M, Mortazavi Y, Kaviani S, Arefian E. The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts. Hematology 2014;19:141–7.
16. Golchin N, Khodadi E, Yaghooti SH, Jaseb K, Shahjahani M, Tavakolifar Y, et al. Immunophenotype, microRNA expression and cytogenetic characterization of acute leukemias of ambiguous lineage. Comparative Clinical Pathology 2017;1;26:261–7.
17. Satpathy AT, Chang HY. Long noncoding RNA in hematopoiesis and immunity. Immunity 2015;42:792–804.
18. Zhang E, Li W, Yin D, De W, Zhu L, Sun S, et al. c-Myc-regulated long non-coding RNA H19 indicates a poor prognosis and affects cell proliferation in non-small-cell lung cancer. Tumor Biology 2016;37:4007–15.
19. Alvarez‐Dominguez J, Lodish H. Unravelling of the role of long noncoding RNAs in haematopoiesis. ISBT Science Series. 2016;11:188–95.
20. Núnêz C, Bashein AM, Brunet CL, Hoyland JA, Freemont AJ, Buckle AM, et al. Expression of the imprinted tumour‐ suppressor gene H19 is tightly regulated during normal haematopoiesis and is reduced in haematopoietic precursors of patients with the myeloproliferative disease polycythaemia vera. The Journal of pathology 2000;190:61–8.
21. Wu J, Zhao J, Sun L, Pan Y, Wang H, Zhang W-B. Long non-coding RNA H19 mediates mechanical tension-induced osteogenesis of bone marrow mesenchymal stem cells via FAK by sponging miR-138. Bone 2018;108:62–70.
22. Helsmoortel HH, De Moerloose B, Pieters T, Ghazavi F, Bresolin S, Cavé H, et al. LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19. Haemato-ogica 2016;101:e240–e4.
23. Takeuchi S, Hofmann WK, Tsukasaki K, Takeuchi N, Ikezoe T, Matsushita M, et al. Loss of H19 imprinting in adult T‐ cell leukemia/lymphoma. British Journal of Hematology 2007;137:380–1.
24. Zhao X, Yang L, Hu J, Ruan J. miR-138 might reverse multidrug resistance of leukemia cells. Leukemia research 2010;34:1078–82.
25. Ye D, Wang G, Liu Y, Huang W, Wu M, Zhu S, et al. MiR‐138 Promotes Induced Pluripotent Stem Cell Generation Through the Regulation of the p53 Signaling. Stem Cells 2012;30:1645–54.
26. Sun Y, Pan J, Zhang N, Wei W, Yu S, Ai L. Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-κB pathway. Scientific reports 2017;7:18079.
27. Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, et al. Control of somatic tissue differentiation by the long noncoding RNA TINCR. Nature 2013;493:231–5.
28. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, et al. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood 1998; 91:3144–7.
29. Raveh E, Matouk IJ, Gilon M, Hochberg A. The H19 Long noncoding RNA in cancer initiation, progression and metastasis–a proposed unifying theory. Molecular cancer 2015;14:184.
30. Wu H-K, Weksberg R, Minden MD, Squire JA. Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia. Biochemical and biophysical research communications 1997;231:466–72.
31. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Molecular Cell 2011;43:904–14.
32. Tsai M-C, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Research 2011;71:3–7.
33. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464:1071–6.
34. Tsai M-C, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010;329:689–93.
35. El Hajj J, Nguyen E, Liu Q, Bouyer C, Adriaenssens E, Hilal G, Ségal-Bendirdjian E. Telomerase regulation by the long noncoding RNA H19 in human acute promyelocytic leukemia cells. Molecular cancer 2018;17:85.
36. Zhang TJ, Zhou JD, Zhang W, Lin J, Ma JC, Wen XM, Yuan Q, Li XX, Xu ZJ, Qian J. H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia. Clinical epigenetics 2018;10:47.
37. Lin J, Ma JC, Yang J, Yin JY, Chen XX, Guo H, Wen XM, Zhang TJ, Qian W, Qian J, Deng ZQ. Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression. Oncogene 2018;37:2432.